XBiotech Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
XBIT$1.91+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share data)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 · 2022 | |||
| Revenue: | |||
| Manufacturing revenue | $ | - | $4,010 |
| Total revenue | - | 4,010 | |
| Cost of goods sold: | |||
| Manufacturing cost | - | 651 | |
| Total cost of goods sold | - | 651 | |
| Gross margin | - | 3,359 | |
| Operating expenses: | |||
| Research and development | 32,848 | 31,544 | |
| General and administrative | 4,662 | 6,305 | |
| Total operating expenses | 37,510 | 37,849 | |
| Loss from operations | (37,510) | (34,490) | |
| Other income: | |||
| Interest income | 10,421 | 3,823 | |
| Other income (expense) | 883 | (121) | |
| Foreign exchange gain (loss) | 1,893 | (2,800) | |
| Total other income | 13,197 | 902 | |
| Loss before income taxes | (24,313) | (33,588) | |
| Income tax (expense) benefit | (244) | 688 | |
| Net loss | $(24,557) | $(32,900) | |
| Net loss per share—basic | $(0.81) | $(1.08) | |
| Shares used to compute basic net loss per share | 30,438,459 | 30,439,275 | |
| Net loss per share—diluted | $(0.81) | $(1.08) | |
| Shares used to compute diluted net loss per share | 30,438,459 | 30,439,275 | |
XBiotech Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.